ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
사구체신염 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 예측 기간의 성장은 자가 면역 질환 환자의 급증 등에 기인한다고 생각됩니다. 이 기간에 예상되는 주요 동향으로는 새로운 치료법의 도입, 진단 기술의 발전, 신규 치료의 개발, 기업간의 협력 관계의 강화, 면역글로불린 정주 요법의 보급 등을 들 수 있습니다.
신장 장애의 유병률 증가가 사구체신염 시장의 성장을 견인할 것으로 예측됩니다. 질병의 이환율 증가는 인구 고령화, 당뇨병 및 고혈압과 같은 만성 질환의 이환율 증가, 생활 습관 등의 요인과 관련이 있습니다. 예를 들어 2024년 12월 호주 보건 복지 연구소는 만성 신장 질환(CKD) 사망률이 2021년에 4.2%, 2022년에 6.2% 증가했다고 보고했습니다.
사구체신염 시장의 주요 기업은 암메트 메디컬 요구를 충족시키고 환자의 결과를 개선하기 위해 혁신적인 비 면역 억제 치료의 개발에 주력하고 있습니다. 2024년 9월 미국 의약품회사인 트라베르세라퓨틱스사는 일반적인 신장병인 IgA 신증의 치료로서 FDA의 승인을 취득한 FILSPARI(sparsentan)를 출시했습니다. FILSPARI는 이환 환자의 신장 기능 저하를 유의하게 지연시키는 것으로 입증 된 유일한 비 면역 억제 치료입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 사구체신염 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 사구체신염 시장 : 성장률 분석
세계의 사구체신염 시장 실적 : 규모와 성장(2019-2024년)
세계의 사구체신염 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 사구체신염 전체 시장(TAM)
제6장 시장 세분화
세계의 사구체신염 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
급성 사구체신염
만성 사구체신염
세계의 사구체신염 시장 : 진단별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
소변 및 혈액검사
영상 검사
신장 생검
기타
세계의 사구체신염 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
약물
수술
투석
기타
세계의 사구체신염 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
기타
세계의 사구체신염 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
기타
세계의 사구체신염 시장 : 급성 사구체신염 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
감염 후 사구체신염
IgA 신증
루푸스 신염
급속 진행성 사구체신염(RPGN)
굿파스퇴르 증후군
세계의 사구체신염 시장 : 만성 사구체신염 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
국소 분절성 사구체 경화증(FSGS)
막성 신증
최소 변화 질환
알포트 증후군
당뇨병성 신증
고혈압성 신경화증
제7장 지역별/국가별 분석
세계의 사구체신염 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 사구체신염 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
사구체신염 시장 : 경쟁 구도
사구체신염 시장 : 기업 프로파일
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
AstraZeneca PLC
Novartis International AG
Eli Lilly and Company
제31장 기타 주요 기업 및 혁신 기업
Asahi Kasei Medical Co. Ltd.
Boehringer Ingelheim International GmbH
DaVita Inc.
Biogen Inc.
Merit Medical Systems Inc.
Apellis Pharmaceuticals Inc.
MorphoSys AG
Travere Therapeutics Inc.
Vera Therapeutics Inc.
Calliditas Therapeutics AB
Omeros Corporation
Otsuka Pharmaceutical Co. Ltd.
Aurinia Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc.
NovelMed Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 전략
사구체신염 시장(2029년) : 새로운 기회를 제공하는 국가
사구체신염 시장(2029년) : 새로운 기회를 제공하는 부문
사구체신염 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Glomerulonephritis is a kidney disorder characterized by inflammation of the glomeruli, the tiny filters in the kidneys responsible for removing waste and excess fluids from the blood. It can be caused by infections, autoimmune diseases, or other underlying conditions, leading to symptoms such as blood in the urine, proteinuria, and swelling. If left untreated, it can progress to chronic kidney disease or kidney failure.
The primary types of glomerulonephritis include acute and chronic glomerulonephritis. Acute glomerulonephritis is a sudden inflammation of the kidneys, often triggered by infections, and requires prompt treatment to prevent long-term complications. Diagnosis is conducted through various methods, including urine and blood tests, imaging tests, and kidney biopsy. Treatment options include medication, surgery, dialysis, and other interventions. The condition is managed through multiple distribution channels, including hospital pharmacies and retail pharmacies, and is utilized by various end-users such as hospitals and specialty clinics.
The glomerulonephritis market research report is one of a series of new reports from The Business Research Company that provides glomerulonephritis market statistics, including the glomerulonephritis industry global market size, regional shares, competitors with the glomerulonephritis market share, detailed glomerulonephritis market segments, market trends, and opportunities, and any further data you may need to thrive in the glomerulonephritis industry. This glomerulonephritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The glomerulonephritis market size has grown strongly in recent years. It will grow from $11.06 billion in 2024 to $11.64 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth during the historic period was driven by the rising prevalence of kidney disorders, the occurrence of infections such as post-streptococcal glomerulonephritis, increased research and development efforts, a higher incidence of kidney failure, and greater awareness of kidney diseases.
The glomerulonephritis market size is expected to see strong growth in the next few years. It will grow to $14.14 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The projected growth in the forecast period can be attributed to the increasing incidence of diabetes, an aging population, rising healthcare expenditures, a growing number of dialysis patients, and a surge in autoimmune disease cases. Key trends expected during this period include the introduction of new treatments and therapies, advancements in diagnostic technologies, the development of novel therapeutics, increased collaboration between companies, and the growing use of intravenous immunoglobulin therapy.
The increasing prevalence of kidney disorders is expected to drive the growth of the glomerulonephritis market. Kidney disorders encompass a range of conditions that impair the kidneys' ability to filter waste, maintain fluid balance, and regulate essential bodily functions. The rising incidence of these disorders is linked to factors such as aging populations, increasing rates of chronic diseases such as diabetes and hypertension, and lifestyle habits. Kidney disorders contribute to glomerulonephritis by triggering immune system dysfunction, chronic inflammation, or structural damage, ultimately leading to impaired kidney function. For example, in December 2024, the Australian Institute of Health and Welfare reported that chronic kidney disease (CKD) mortality rates increased by 4.2% in 2021 and 6.2% in 2022. Additionally, CKD was recorded in approximately 2 million hospitalizations in 2021-22, accounting for 18% of all hospitalizations in Australia. As kidney disorders become more prevalent, the demand for glomerulonephritis treatments is expected to rise.
Leading companies in the glomerulonephritis market are focusing on developing innovative non-immunosuppressive treatments to meet unmet medical needs and improve patient outcomes. Non-immunosuppressive treatments are designed to treat conditions without compromising immune function. In September 2024, Travere Therapeutics Inc., a US-based biopharmaceutical company, launched FILSPARI (sparsentan), which received FDA approval for treating IgA nephropathy, a common kidney disease. FILSPARI is the only non-immunosuppressive treatment proven to significantly slow the decline of kidney function in affected patients. This approval marks a significant advancement in the treatment of IgA nephropathy, providing a new option for patients who previously had limited choices. Travere's success reflects a growing commitment to developing innovative therapies for kidney disease.
In May 2023, Rona Therapeutics Inc., a China-based biopharmaceutical company, entered into a partnership with Keymed Biosciences Inc. to develop novel treatments for glomerulonephritis. This collaboration focuses on creating first-in-class siRNA therapeutics to address the urgent need for new medicines in this field. Keymed Biosciences Inc., also based in China, specializes in biotechnology and is dedicated to advancing treatments for glomerulonephritis.
Major players in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Asahi Kasei Medical Co. Ltd., Boehringer Ingelheim International GmbH, DaVita Inc., Biogen Inc., Merit Medical Systems Inc., Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., and NovelMed Therapeutics Inc.
North America was the largest region in the glomerulonephritis market in 2024. The regions covered in glomerulonephritis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the Glomerulonephritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The glomerulonephritis market consists of revenues earned by entities by providing services such as immunosuppressive therapy, blood pressure control, and kidney transplants. The market value includes the value of related goods sold by the service provider or included within the service offering. The glomerulonephritis market also includes sales of complement-level test kits, urine protein test kits, and medication. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Glomerulonephritis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on glomerulonephritis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for glomerulonephritis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glomerulonephritis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Acute Glomerulonephritis; Chronic Glomerulonephritis
2) By Diagnosis: Urine And Blood Tests; Imaging Tests; Kidney Biopsy; Other Diagnosis
3) By Treatment: Medication; Surgery; Dialysis; Other Treatments
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
5) By End-User: Hospitals; Specialty Clinics; Other End-Users
Subsegments:
1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis; IgA Nephropathy; Lupus Nephritis; Rapidly Progressive Glomerulonephritis (RPGN); Goodpasture Syndrome
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Glomerulonephritis Market Characteristics
3. Glomerulonephritis Market Trends And Strategies
4. Glomerulonephritis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Glomerulonephritis Growth Analysis And Strategic Analysis Framework
5.1. Global Glomerulonephritis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Glomerulonephritis Market Growth Rate Analysis
5.4. Global Glomerulonephritis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Glomerulonephritis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Glomerulonephritis Total Addressable Market (TAM)
6. Glomerulonephritis Market Segmentation
6.1. Global Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Glomerulonephritis
Chronic Glomerulonephritis
6.2. Global Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Urine And Blood Test
Imaging Tests
Kidney Biopsy
Other Diagnosis
6.3. Global Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medication
Surgery
Dialysis
Other Treatments
6.4. Global Glomerulonephritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Other Distribution Channels
6.5. Global Glomerulonephritis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Other End-Users
6.6. Global Glomerulonephritis Market, Sub-Segmentation Of Acute Glomerulonephritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Post-infectious Glomerulonephritis
IgA Nephropathy
Lupus Nephritis
Rapidly Progressive Glomerulonephritis (RPGN)
Goodpasture Syndrome
6.7. Global Glomerulonephritis Market, Sub-Segmentation Of Chronic Glomerulonephritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Focal Segmental Glomerulosclerosis (FSGS)
Membranous Nephropathy
Minimal Change Disease
Alport Syndrome
Diabetic Nephropathy
Hypertensive Nephrosclerosis
7. Glomerulonephritis Market Regional And Country Analysis
7.1. Global Glomerulonephritis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Glomerulonephritis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
